GSK grants deferred award to new Chief People Officer

GSK plc granted a deferred investment award to new Chief People Officer and Executive Committee member Roanne Parry.

Rhea-AI Filing Summary

GSK plc granted a deferred investment award to new Chief People Officer and Executive Committee member Roanne Parry. The award is over notional Ordinary Shares, referenced to 35,507.628 shares at a price of £19.01 per share, and is intended to align long term with shareholders.

The award vests in two stages, with 34.22% scheduled to vest on 31 August 2028 and 65.78% on 31 August 2029, provided Ms Parry has not resigned or been terminated for cause. Dividends will accrue during the vesting period, and the benefit will be settled in cash on vesting.

Key Figures

Notional award volume: 35,507.628 shares Reference share price: £19.01 per share First vesting tranche: 34.22% +2 more

5 metrics

Notional award volume 35,507.628 shares Notional Ordinary Shares under Deferred Investment Award

Reference share price £19.01 per share Price used for notional Ordinary Shares

First vesting tranche 34.22% Scheduled to vest on 31 August 2028

Second vesting tranche 65.78% Scheduled to vest on 31 August 2029

Transaction date 2026-05-01 Grant date of notional award to Roanne Parry

Key Terms

Deferred Investment Award programme, notional Ordinary Shares, Person Discharging Managerial Responsibilities, vesting period, +1 more

5 terms

Deferred Investment Award programme financial

"under the GlaxoSmithKline Deferred Investment Award programme"

notional Ordinary Shares financial

"granted an award over notional Ordinary Shares to Roanne Parry"

Person Discharging Managerial Responsibilities regulatory

"to Roanne Parry, a Person Discharging Managerial Responsibilities ('PDMR')"

A person discharging managerial responsibilities is an individual who holds a senior role with authority to make or influence a company’s strategic or operational decisions, such as executives, board members, or other top managers. Investors care because these people often have access to confidential information and their buying or selling of company shares must be disclosed—like a referee who knows the score before the crowd, their actions can signal important, non-public insights about a company's prospects.

vesting period financial

"awards are made over notional Ordinary Shares with vesting over a specified period"

A vesting period is the set amount of time someone must wait before they fully own granted shares, stock options, or other equity tied to their work or an agreement; ownership increases gradually or in steps during that time. Investors care because vesting determines when insiders or employees can sell shares, which affects future supply of stock, company incentives and executive retention—think of it like unlocking ownership over installments rather than receiving it all at once.

dividends will accrue financial

"Dividends will accrue on the award during the vesting period"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What executive award did GSK (GSK) disclose in this Form 6-K?

GSK disclosed a deferred investment award granted to Chief People Officer Roanne Parry. It is a notional award over Ordinary Shares under the Deferred Investment Award programme, designed to provide long-term alignment with shareholders and paid out in cash on vesting.

How many notional shares were granted to GSK (GSK) executive Roanne Parry?

The award for Roanne Parry is referenced to 35,507.628 notional Ordinary Shares at a price of £19.01 per share. These notional shares determine the cash value on vesting, with dividends accruing over the vesting period before payment.

When will the GSK (GSK) deferred investment award to Roanne Parry vest?

The award vests in two tranches: 34.22% on 31 August 2028 and 65.78% on 31 August 2029. Vesting depends on Ms Parry not having given notice of resignation and not being terminated by the company for cause.

How will the GSK (GSK) deferred investment award be settled on vesting?

Although structured over notional Ordinary Shares, the award will be paid in cash when it vests. Dividends that would have been paid on the underlying shares accrue during the vesting period and are included in the final cash settlement to the executive.

What conditions apply to Roanne Parry’s GSK (GSK) deferred award vesting?

Vesting is conditional on the PDMR, Roanne Parry, not having served notice to GSK and not being terminated for cause. These conditions support retention by linking the award’s value to continued employment over the multi-year vesting schedule.

Are GSK (GSK) Executive Directors eligible for the Deferred Investment Award programme?

Executive Directors are not eligible to receive awards under GSK’s Deferred Investment Award programme. The disclosed grant relates specifically to Roanne Parry, the Chief People Officer and a newly appointed member of the Executive Committee, rather than to Board-level Executive Directors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/05/2026 - 12:54 PM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

2026 Award under the Deferred Investment Award Programme

Notional Award

On 1 May 2026, the Company granted an award over notional Ordinary Shares to Roanne Parry, a Person Discharging Managerial Responsibilities ('PDMR'), under the GlaxoSmithKline Deferred Investment Award programme. The award has been granted upon Ms Parry joining GSK as Chief People Officer and a newly appointed Executive Committee member.

Under the programme, awards are made over notional Ordinary Shares with vesting over a specified period to provide long-term alignment with shareholders. Vesting is subject to the PDMR not having served the Company notice or having been terminated by the Company for cause. Dividends will accrue on the award during the vesting period. On vesting, the award will be paid in cash. The award will vest in two increments: 34.22% of the award will vest on 31 August 2028 and 65.78% of the award will vest on 31 August 2029.

Executive Directors are not eligible to receive awards under the programme.

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Roanne Parry
b)	Position/status	Chief People Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	A restricted award of notional Ordinary Shares under the Company's Deferred Investment Award programme.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£19.01	35,507.628
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-05-01
f)	Place of the transaction	N/A

​ 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: May 05, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc